网站地图 联系我们搜索内部网English | 中国科学院
首页 所况简介 机构设置 科研队伍 科学研究平台 院地合作 党群园地 国际交流 博士后 研究生教育 科学传播 信息公开
现在位置:首页 > 课题组长 > 姓氏首字母A-G

  傅阳心 博士 研究员 博士生导师

  国家“千人计划”获得者

  中科院生物物理所,中科院感染与免疫重点实验室,创新课题组组长(客座)

  德克萨斯大学西南医学中心病理与免疫系教授

  研究方向:肿瘤免疫治疗

  电子邮件(E-mail)  yangxinfu100@gmail.com 

  电话(Tel) 010-64881152,邮政编码 100101

  英文版个人网页  

  简历 & 研究组工作摘要

  1979-1983  上海医科大学,医学学士

  1983-1986  中国医学科学院北京协和医学院, 住院医师

  1986-1990  美国迈阿密大学医学院,博士

  1991-1993  美国丹佛市国立犹太人免疫与呼吸医学中心,博士后

  1994-1998  美国华盛顿大学医学院, 住院医师

  1998-2005  美国芝加哥大学,助理教授

  2005-2015  美国芝加哥大学,教授

  2015-      美国德克萨斯大学西南医学中心,教授

  2004-      中国科学院生物物理研究所,研究员(客座)

  研究方向

  本课题组主要研究方向包括以下几个方面:

  1)肿瘤免疫治疗;2)新型抗肿瘤抗体;3)慢性病毒感染的免疫治疗策略研究;4)淋巴毒素和肠道免疫。

  课题组成员如下:

 傅阳心  博士,教授,高级研究顾问
 彭华  博士,研究员,电子邮件:hpeng@moon.ibp.ac.cn
 梁永  博士,博士后
 孟朝阳  博士,助理研究员
 郭静雅  在职博士生,工程师
 徐海蓉  硕士,助理研究员
 博士生  刘晓娟、杨凯婷、孙志辰、曹帅帅
 硕博连读生  薛薛娣媛、孙士玉、林逸凡、邹壮志

  代表性论文

  PD-L1 on host cells is essential for tumor regression mediated by PD-L1 blockade. Haidong Tang#, Yong Liang#, Robert Anders, Janis M. Taube, Xiangyan Qiu, Aditi Mulgaonkar, Xin Liu, Susan Harrington, Jingy Guo, Yangchun Xin, Yahong Xiong, Kien Nham, William Silvers, Guiyang Hao, Xiankai Sun, Mingyi Chen, Raquibul Hannan, Jian Qiao, Haidong Dong*, Hua Peng*, Yang-Xin Fu*, J Clin Invest. 2018 Jan 16. pii: 96061. doi: 10.1172/JCI96061.

  Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Liao J, Luan Y, Ren Z, Liu X, Xue D, Xu H, Sun Z, Yang K, Peng H*, Fu YX*. Cancer Immunol Res. 2017 Jul 5(7) 560-570

  Vaccines targeting preS1 domain overcome immune tolerance in hepatitis B virus carrier mice. Bian Y, Zhang Z, Sun Z, Zhao J, Zhu D, Wang Y, Fu S, Guo J, Liu L, Su L, Wang FS, Fu YX*, Peng H*. Hepatology. 2017 Oct 66(4) 1067-1082

  CTLA-4 limits anti-CD20-mediated tumor regression. Ren Z, Guo J, Liao J, Luan Y, Liu Z, Sun Z, Liu X, Liang Y, Peng H, Fu YX, Clin. Cancer Res. 2016 Jun

  Combination of radiotherapy and vaccination overcome checkpoint blockade resistance. Zheng W, Skowron KB, Namm JP, Burnette B, Fernandez C, Arina A, Liang H, Spiotto MT, Posner MC, Fu YX, Weichselbaum RR Oncotarget 2016 Jun

  PD-1 Shapes B Cells as Evildoers in the Tumor Microenvironment. Ren Z, Peng H, Fu YX, Cancer Discov 2016 May 6 5 477-8

  Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse. Pu Y, Xu M, Liang Y, Yang K, Guo Y, Yang X, Fu YX, Sci Transl Med 2016 Apr 8 333 333ra47

  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. Tang H, Wang Y, Chlewicki LK, Zhang Y, Guo J, Liang W, Wang J, Wang X, Fu YX, Cancer Cell 2016 Mar 29 3 285-96

  Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination. Zhu D, Liu L, Yang D, Fu S, Bian Y, Sun Z, He J, Su L, Zhang L, Peng H*, Fu YX*. J Immunol. 2016 Apr 1 196(7) 3079-87

  CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM, Nat. Med. 2015 Oct 21 10 1209-15

  Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication. Liang Y, Yang K, Guo J, Wroblewska J, Fu YX*, Peng H*, Sci Rep 2015 May 20 5 10406

  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, Li XD, Mauceri H, Beckett M, Darga T, Huang X, Gajewski TF, Chen ZJ, Fu YX, Weichselbaum RR Immunity 2014 Nov 41 5 843-52

  Innate lymphoid cells facilitate NK cell development through a lymphotoxin-mediated stromal microenvironment. Kim TJ, Upadhyay V, Kumar V, Lee KM, Fu YX, J. Exp. Med. 2014 Jun 211 7 1421-31

  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX, J. Clin. Invest. 2014 Feb 124 2 687-95

  Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses. Yang X, Zhang X, Fu ML, Weichselbaum RR, Gajewski TF, Guo Y, Fu YX, Cancer Cell. 2014 Jan 25 1 37-48

  A mouse model for HBV immunotolerance and immunotherapy. Yang D, Liu L, Zhu D, Peng H, Su L, Fu YX, Zhang L. Cell Mol Immunol. 2014 Jan 11 1 71-8

  Effective anti-neu initiated anti-tumor responses require the complex role of CD4+ T cells. Mortenson E, Park S, Zhujun J, Wang S, Fu YX, Clin. Cancer Res. 2013 Jan

  Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. Yang X, Zhang X, Mortenson ED, Radkevich-Brown O, Wang Y, Fu YX, Mol. Ther. 2013 Jan 21 1 91-100

  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN, Weichselbaum RR, Fu YX, Auh SL Cancer Res.2011 Apr 71 7 2488-96

  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S, Fu YX, Cancer Cell 2010 Aug 18 2 160-70

  Promoting immune responses by LIGHT in the face of abundant regulatory T cell inhibition. Wang Y, Zhu M, Yu P, Fu YX, J. Immunol. 2010 Feb 184 3 1589-95

  Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, Beckett M, Sharma R, Chin R, Tu T, Weichselbaum RR, Fu YX, Blood 2009 Jul 114 3 589-95

  Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. Yu P, Lee Y, Wang Y, Liu X, Auh S, Gajewski TF, Schreiber H, You Z, Kaynor C, Wang X, Fu YX, J. Immunol. 2007 Aug 179 3 1960-8

  Lymphotoxin beta receptor-dependent control of lipid homeostasis. Lo JC, Wang Y, Tumanov AV, Bamji M, Yao Z, Reardon CA, Getz GS, Fu YX. Science. 2007 Apr 13;316(5822):285-8.

  NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Fan Z, Yu P, Wang Y, Wang Y, Fu ML, Liu W, Sun Y, Fu YX, Blood 2006 Feb 107 4 1342-51

  Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX, J. Exp. Med. 2005 Mar 201 5 779-91

  Priming of naive T cells inside tumors leads to eradication of established tumors. Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX, Nat. Immunol. 2004 Feb 5 2 141-9

    

  资料来源:傅阳心研究员,2018-01-26网页更新 

                 
版权所有:中国科学院生物物理研究所     京ICP备05002792号 京公网安备 110402500011 号
地址:北京市朝阳区大屯路15号(100101) 电话:010-64889872
意见反馈联系人:马秋云 电子邮件:maqiuyun@moon.ibp.ac.cn